Skip to main content
SpringerLink
Log in

Evolving role of leukotrienes in the pathogenesis of viral infections, including otitis media

  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

Otitis media (OM) is one of the most common childhood disorders and has been associated with an alarming rise in prevalence. Because medical therapy with antibiotics, antihistamines, decongestants, and corticosteroids has no demonstrable efficacy in the treatment of OM, the mainstay of treatment is surgical intervention. Although effective, surgical treatment is quite expensive and exposes patients to the risks associated with general anesthesia. Results of recent studies suggest that locally produced leukotrienes may play a role in the pathogenesis of OM. As such, a potential candidate for treatment of OM is the leukotriene receptor antagonist, montelukast, which has been approved by the US Food and Drug Administration for the treatment of asthma and/or allergic rhinitis. If proven effective, this drug’s safety/ convenience profiles and indication for children as young as 6 months of age would make it suitable for treatment of OM, and perhaps even prophylaxis of OM in at-risk populations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Auinger P, Lanphear BP, Kalkwarf HJ, Mansour ME: Trends in otitis media among children in the United States. Pediatrics 2003, 112:514–520. This publication discusses the prevalence of OM in children in the United States.

    Article  PubMed  Google Scholar 

  2. Cayce KA, Krowchuk DP, Feldman SR, et al.: Healthcare utilization for acute and chronic diseases of young, school-age children in the rural and non-rural setting. Clin Pediatr 2005, 44:491–498. This publication summarizes the economic impact of OM in children in the United States.

    Article  Google Scholar 

  3. Agrawal S, Husein M, MacRae D: Complications of otitis media: an evolving state. J Otolaryngol 2005, 34S1:S33-S39.

    Google Scholar 

  4. Klein JO: The burden of otitis media. Vaccine 2000, 19:S2-S8.

    Article  PubMed  Google Scholar 

  5. Paramore LC, Ciuryla V, Ciesla G, Liu L: Economic impact of RSV-related illness in the US: an analysis of national databases. Pharmacoeconomics 2004, 22:275–284.

    Article  PubMed  Google Scholar 

  6. Adams JC: Clinical implications of inflammatory cytokines in the cochlea: a technical note. Otol Neurotol 2002, 23:316–322.

    Article  PubMed  Google Scholar 

  7. Barkdull GC, Vu C, Keithley EM, Harris JP: Cochlear microperfusion: experimental evaluation of a potential new therapy for severe hearing loss caused by inflammation. Otol Neurotol 2005, 26:19–26.

    Article  PubMed  Google Scholar 

  8. Anon JB, Ripple WL, Jacobs MR: Failure of a 5-day course of intramuscular ceftriaxone to eradicate Streptococcus pneumoniae from the middle ear. Pediatr Infect Dis J 2006, 25:181–182.

    Article  PubMed  Google Scholar 

  9. Butler CC, Van Der Voort JH: Oral or topical nasal steroids for hearing loss associated with otitis media with effusion in children. Cochrane Database Syst Rev 2000, 4:CD001935.

  10. Westerberg BD, Morzaria S, Kozak FK, Price D: Medical management of middle ear disease in children less than 2 years of age with sensorineural hearing loss. J Otolaryngol 2005, 34S2:S64-S69.

    Google Scholar 

  11. Hammaren-Malmi S, Saxen H, Tarkkanen J, Mattila PS:Adenoidectomy does not significantly reduce the incidence of otitis media in conjunction with the insertion of tympanostomy tubes in children who are younger than 4 years: a randomized trial. Pediatrics 2005, 116:185–189.

    Article  PubMed  Google Scholar 

  12. Stenstrom R, Pless IB, Bernard P: Hearing thresholds and tympanic membrane sequelae in children managed medically or surgically for otitis media with effusion. Arch Pediatr Adolesc Med 2005, 159:1151–1156.

    Article  PubMed  Google Scholar 

  13. Glasziou PP, Del Mar CB, Sanders SL, Hayem M: Antibiotics for acute otitis media in children. Cochrane Database Syst Rev 2004, CD000219. The results of this meta-analysis demonstrate the marginal efficacy of antibiotics in treating OM.

  14. Skoner DP, et al.: Otitis media. In Middleton’s Allergy Principles and Practice. Edited by Adkinson NF, et al. Philadelphia: Mosby; 2003, 1437–1454. This chapter reviews the pathogenesis of OM in detail.

    Google Scholar 

  15. Buchman C, Doyle WJ, Skoner D, et al.: Otologic manifestations of experimental rhinovirus infection. Laryngoscope 1994, 104:1295–1299.

    PubMed  CAS  Google Scholar 

  16. Doyle WJ, Skoner DP, Hayden F, et al.: Nasal and otologic effects of experimental influenza A virus infection. Ann Otol Rhinol Laryngol 1994, 103:59–69.

    PubMed  CAS  Google Scholar 

  17. Belshe RB, Mendelman PM, Treanor J, et al.: The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 1998, 338:1405–1412.

    Article  PubMed  CAS  Google Scholar 

  18. Simoes EA, Groothuis JR, Tristram DA, et al.: Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high risk children. J Pediatr 1996, 129:214–219.

    Article  PubMed  CAS  Google Scholar 

  19. Walker JB, Hussey EK, Treanor JJ, et al.: Effects of the neuraminidase inhibitor zanamavir on otologic manifestations of experimental human influenza. J Infect Dis 1997, 176:1417–1422.

    Article  PubMed  CAS  Google Scholar 

  20. Doyle WJ, Skoner DP, Alper CM, et al.: Effect of rimantadine treatment on clinical manifestions and otologic complications in adults experimentally infected with influenza A (H1N1) virus. J Infect Dis 1998, 177:1260–1265.

    Article  PubMed  CAS  Google Scholar 

  21. Yellon RF, et al.: Otolaryngology. In Atlas of Pediatric Physical Diagnosis, edn 4. Edited by Zitelli B, Davis H. Philadelphia: Mosby; 2002:818–866.

    Google Scholar 

  22. Buchman CA, Doyle WJ, Skoner DP, et al.: Influenza A virus-induced acute otitis media. J Infect Dis 1995, 172, 1348–1351.

    PubMed  CAS  Google Scholar 

  23. Turner RB, Darden PM: Effect of topical adrenergic decongestants on middle ear pressure in infants with common colds. Pediatr Infect Dis J 1996, 15:621–625.

    Article  PubMed  CAS  Google Scholar 

  24. Behera AK, Kumar M, Matsuse H, et al.: Respiratory syncytial virus induces the expression of 5-lipoxygenase and endothelin-1 in bronchial epithelial cells. Biochem Biophys Res Comm 1998, 251:704–709.

    Article  PubMed  CAS  Google Scholar 

  25. van Schaik SM, Tristram DA, Nagpal IS, et al.: Increased production of IFN-gamma and cysteinyl leukotrienes in virus-induced wheezing. J Allergy Clin Immunol 1999, 103:630–636.

    Article  PubMed  Google Scholar 

  26. Turner RB, Weingand KW, Chyon-Hwa Y, Leedy DW: Association between interleukin-8 concentration in nasal secretions and severity of symptoms of experimental rhinovirus colds. Clin Infect Dis 1998, 26:840–846.

    PubMed  CAS  Google Scholar 

  27. Gentile DA, Fireman P, Skoner DP, et al.: Elevations of local leukotriene C4 levels during viral upper respiratory infections. Ann Allergy Asthma Immunol 2003, 91:270–274. The results of this study demonstrate a temporal relationship between elevations of local leukotriene levels and the development of vURI signs/symptoms following experimental infection with respiratory viruses.

    Article  PubMed  CAS  Google Scholar 

  28. Naclerio RM, Baroody FM, Togias AG: The role of leukotrienes in allergic rhinitis: a review. Am Rev Respir Dis 1991, 143:S91-S95.

    PubMed  CAS  Google Scholar 

  29. Doyle WJ, Skoner DP, Gentile D: Nasal cytokines as mediators of illness during the common cold. Curr Allergy Asthma Rep 2005, 5:173–181. This review article summarizes the role of nasal cytokines as mediators of signs/symptoms of vURIs.

    Article  PubMed  CAS  Google Scholar 

  30. Ihaku D, Cameron L, Suzuki M, et al.: Montelukast, a leukotriene receptor antagonist, inhibits the late airway response to airway eosinophilia, and IL-5 expressing cells in Brown Norway rats. J Allergy Clin Immunol 1999, 104:1147–1154.

    Article  PubMed  CAS  Google Scholar 

  31. Combs JT: The effect of montelukast sodium on the duration of effusion of otitis media. Clin Pediatr 2004, 43:529–533. The results of this randomized, double-blinded, placebo-controlled trial demonstrate efficacy of a leukotriene modifier in the treatment of OM.

    Article  Google Scholar 

  32. Balatsouras DG, Eliopoulos P, Rallis E, et al.: Improvement of otitis media with effusion after treatment of asthma with leukotriene antagonists in children with co-existing disease. Drugs Exp Clin Res 2005, 31S:7–10.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Allergy, Asthma and Immunology, Allegheny General Hospital, 320 E North Avenue, 15212, Pittsburgh, PA, USA

    Deborah Gentile MD

Authors
  1. Deborah Gentile MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gentile, D. Evolving role of leukotrienes in the pathogenesis of viral infections, including otitis media. Curr Allergy Asthma Rep 6, 316–320 (2006). https://doi.org/10.1007/s11882-006-0066-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11882-006-0066-8

Keywords

Search

Navigation